Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Nov;14(11):874-9.
doi: 10.3779/j.issn.1009-3419.2011.11.08.

[Current status and future direction of multi-targeted drugs in the era of personalized therapy--overview of advances in multi-targeted therapy in non-small cell lung cancer]

[Article in Chinese]
Caicun Zhou  1
Affiliations
Review

[Current status and future direction of multi-targeted drugs in the era of personalized therapy--overview of advances in multi-targeted therapy in non-small cell lung cancer]

[Article in Chinese]
Caicun Zhou. Zhongguo Fei Ai Za Zhi. 2011 Nov.

Abstract
in English, Chinese

Multi-targeted tyrosine kinase inhibitors (TKIs) play important roles in the treatment of non-small cell lung cancer (NSCLC). Recently, results of several large phase III studies have been published, showing bittersweet efficacy of multi-targeted TKIs. In the era of personalized therapy, optimal use of multi-targeted TKIs is worthy of further investigation. In this review, we summarized current clinical development and future direction of multi-targeted TKIs in NSCLC.

目前在非小细胞肺癌治疗中，多靶点药物占有举足轻重的地位。近年来随着多项Ⅲ期临床结果的陆续公布，多靶点药物的疗效可谓喜忧参半。在个体化治疗的大方向下，如何发挥多靶点药物的最佳疗效，的确值得我们探索。本文综述了近年来多靶点药物治疗非小细胞肺癌的最新临床进展，希望能有所启发。

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Eng J Med. 2009;361(10):947–957. doi: 10.1056/NEJMoa0810699. - DOI - PubMed

    1. Zhou C, Wu YL, Chen G, et al. Efficacy results from the randomised phase Ⅲ OPTIMAL(CTONG 0802) study comparing first-line erlotinib versus carboplatin(CBDCA) plus gemcitabine(GEM), in Chinese advanced non-small-cell lung cancer (NSCLC) patients (PTS) with EGFR activating mutations. 35th European Society for Medical Oncology, LBA12.

    1. Gridelli C, Maione P, Del Gaizo F, et al. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist. 2007;12(2):191–200. doi: 10.1634/theoncologist.12-2-191. - DOI - PubMed
    1. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors. http://downloads.hindawi.com/journals/ecam/2013/718380.xml. Clin Cancer Res. 2003;9(1):327–337. - PubMed
    1. Herbst RS. Imaging in drug development. https://www.sciencedirect.com/science/article/pii/S0079646814000034. Clin Adv Hematol Oncol. 2004;2(5):268–269. - PubMed

MeSH terms

Substances